🧬 Martin Brenner - iBio - Part 2 | Autonomy at Eli Lilly vs. Structure at Pfizer | Transitioning from AstraZeneca to Merck | Joys & Challenges When Relocating for Work | A Biotech Vision Leading to an Exit From Big Pharma

Part 2 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.